Sagimet Biosciences Inc. financial data

Symbol
SGMT on Nasdaq
Location
San Mateo, CA
Fiscal year end
31 December
Latest financial report
11 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 3.3% % -71%
Return On Equity -41% % -57%
Return On Assets -39% % -52%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30,674,855 shares 44%
Entity Public Float $228,400,000 USD 123%
Weighted Average Number of Shares Outstanding, Basic 32,345,525 shares 3.2%
Weighted Average Number of Shares Outstanding, Diluted 32,345,525 shares 3.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $39,054,000 USD 1.6%
General and Administrative Expense $17,835,000 USD 11%
Operating Income (Loss) $56,889,000 USD -4.5%
Net Income (Loss) Attributable to Parent $51,038,000 USD -12%
Earnings Per Share, Basic -1.58 USD/shares -9%
Earnings Per Share, Diluted -1.58 USD/shares -9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $35,021,000 USD -54%
Marketable Securities, Current $78,103,000 USD 3.6%
Cash, Cash Equivalents, and Short-term Investments $113,100,000 USD -29%
Other Assets, Current $199,000 USD 27%
Assets, Current $116,404,000 USD -24%
Operating Lease, Right-of-Use Asset $78,000 USD 1.3%
Other Assets, Noncurrent $62,000 USD
Assets $116,482,000 USD -27%
Accounts Payable, Current $1,309,000 USD -8.1%
Employee-related Liabilities, Current $1,617,000 USD 19%
Accrued Liabilities, Current $3,714,000 USD 26%
Liabilities, Current $5,101,000 USD 15%
Liabilities $7,180,000 USD 59%
Accumulated Other Comprehensive Income (Loss), Net of Tax $120,000 USD -48%
Retained Earnings (Accumulated Deficit) $346,349,000 USD -17%
Stockholders' Equity Attributable to Parent $111,381,000 USD -29%
Liabilities and Equity $116,482,000 USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,536,000 USD -134%
Net Cash Provided by (Used in) Financing Activities $104,846,000 USD
Net Cash Provided by (Used in) Investing Activities $3,413,000 USD 14%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35,021,000 USD -54%
Deferred Tax Assets, Valuation Allowance $77,410,000 USD 17%
Deferred Tax Assets, Gross $77,426,000 USD 17%
Operating Lease, Liability $78,000 USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $51,148,000 USD -13%
Lessee, Operating Lease, Liability, to be Paid $80,000 USD 0%
Operating Lease, Liability, Current $78,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $80,000 USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $46,665,000 USD 33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $2,341,000 USD 7.1%
Additional Paid in Capital $457,607,000 USD 1.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $16,000 USD 0%
Share-based Payment Arrangement, Expense $6,449,000 USD 22%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%